I'll research AXON before writing the preview. Let me gather recent earnings history, guidance, filings, analyst sentiment, and stock performance.AXON has had a volatile year. Let me read the most recent earnings release/transcript (2026Q1) and the prior-year comparable (2025Q2), plus recent news.Let me get the prior-year Q2 comps and recent news/analyst sentiment.Let me check consensus estimates and recent analyst sentiment for the upcoming print.Let me read the most recent preview article for consensus estimates.I now have what I need. Here's the earnings preview.
Axon comes into this print as a high-multiple compounder that has strung together nine straight quarters of 30%+ revenue growth, but whose stock has been on a rollercoaster — and which is now surging into the report on a wave of AI, counter-drone, and Washington-driven optimism. The question isn't whether the quarter is "good"; it's whether it's good enough versus an extremely high bar, and whether management raises guidance again.
| Metric | Q2 2026 Consensus | Q2 2025 Actual | Implied Y/Y |
|---|---|---|---|
| Revenue | ~$868M | $668.5M | +~30% |
| Non-GAAP EPS | ~$1.89 | $2.12 | −~11% |
| Connected Devices rev | ~$479M | $376.4M | +~27% |
1. Bookings & backlog (the real tell). Revenue is largely a function of a backlog that's already at $14.3B. Watch whether future contracted bookings keep compounding at a rate at/above revenue growth — management has explicitly said that if bookings grow in line with revenue, the ~30% growth algorithm extends far into the future. Q4 is the seasonally huge bookings quarter, so a soft-looking Q2 bookings number is normal; the y/y growth rate is what counts.
2. The guidance raise. Axon raised full-year revenue guidance to 30–32% growth at Q1 (from 27–30%), while holding the ~25.5% adjusted EBITDA margin. Given the stock's momentum, an in-line quarter with no raise could disappoint; a raise toward/above the high end is likely the bull-case trigger. Full-year Street revenue sits around ~$3.65B.
3. Gross margin — the pressure point. Adjusted gross margin was 61.6% in Q1, down ~200 bps y/y, squeezed by (a) global tariffs, (b) memory/component inflation on cameras, and (c) mix shift toward lower-margin Dedrone hardware and professional services. Management said memory isn't big enough to break out and that H2 will bring operating leverage to hit the 25.5% EBITDA target — so look for margin stabilization and whether the "second-half leverage" story is on track.
4. Free cash flow & inventory build. This is the most nuanced issue. Axon burned cash in H1 (Q1 FCF was −$55M) as it deliberately loaded up on inventory to de-risk supply chain and fund Dedrone/international demand. The full-year target is ~$450M of free cash flow, which requires a large H2 swing. Watch inventory levels, working capital, and whether the FCF-conversion narrative holds.
5. Counter-drone (Dedrone) — the new growth leg. Scaling "beyond our most aggressive assumptions." Tailwinds include the Safer Skies Act ($250M in federal grants + local mitigation authority) and marquee events (Super Bowl, Kentucky Derby, 2026 World Cup venues). Management says it's currently supply-constrained, not demand-constrained. Any update on production ramp and margin trajectory here is a key swing factor.
6. AI Era Plan traction. "Nearly all large domestic law enforcement agencies are now including AI in their purchases." AI is off a tiny revenue base but inflecting fast. Watch for updated AI booking figures and adoption of new products unveiled at Axon Week (Axon Vision, Guardian, Assistant, Form One, Brief One).
7. Stock-based compensation & dilution. SBC runs ~$134M/quarter (~$590–620M/yr guide), a persistent bear talking point given GAAP vs. non-GAAP gaps. Management targets <2.5% average annual dilution and says SBC dollars should stay roughly flat, declining as a % of revenue. Keep an eye on the GAAP-to-non-GAAP bridge.
Washington wildcard: News that Axon received a stock purchase of up to $5 million from President Trump, and roughly two weeks later ICE announced it was seeking a 5-year, $220 million contract to more than quadruple its Taser inventory has added a speculative bid. Federal procurement records show no contract has been awarded yet, though experts view Axon as the front-runner given it manufactures the Tasers ICE currently uses. The White House stated there is no conflict of interest and noted Trump's assets are managed by independent third-party firms. Also note an insider Form 144 filing on Aug 4 (intent to sell ~$599K) — routine, but worth flagging into the event.
Bull case - 10th straight 30%+ quarter + another guidance raise. - Bookings/ARR keep compounding (backlog visibility is enormous). - Dedrone and international as durable new growth legs; AI adoption inflecting. - Federal/ICE Taser tailwind provides optionality not yet in numbers.
Bear case - Valuation remains rich after a 24% two-week run; high bar. - Gross-margin erosion (tariffs, memory, Dedrone mix) persists; H2 leverage must show up. - Heavy H1 cash burn / inventory build — FCF target is back-half loaded. - Large SBC and dilution; a "down" y/y EPS headline could spook casual readers. - Government-funding and contract-timing lumpiness (international revenue is explicitly lumpy).
Fundamentally, Axon is executing at an elite level across a widening set of growth vectors, and the backlog, ARR, and bookings give unusual forward visibility. The debate on this print is not the trajectory — it's expectations and price. With shares having surged into the report, the reaction likely hinges on three things: (1) whether management raises full-year guidance again, (2) evidence that gross margins are stabilizing and H2 operating leverage/FCF conversion is intact, and (3) the pace of Dedrone and AI monetization. Anything short of a beat-and-raise with clean margin commentary could see the recent momentum unwind quickly; conversely, a raise plus continued Dedrone/AI/federal momentum could re-open the path back toward the 2025 highs.
Preview based on Axon's Q1 2026 and Q2 2025 results/filings, management commentary, consensus estimates (~$868M revenue / ~$1.89 non-GAAP EPS), recent news, and price history through Aug 4, 2026.